Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATR04-484
- Development stage
- Phase 2
- Lead developer
- Azitra
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
ATR04-484 is a live biotherapeutic product candidate developed by Azitra for the treatment of skin rashes associated with epidermal growth factor receptor inhibitor (EGFRi) therapy. It consists of an engineered auxotrophic strain of Staphylococcus epidermidis (SE484), selected for its ability to inhibit Staphylococcus aureus and reduce IL-36γ levels—both implicated in EGFRi-induced dermal toxicity. The strain has been further modified to enhance safety by deleting an antibiotic resistance gene and engineering D-alanine auxotrophy to control its growth. Applied topically as an ointment, ATR04-484 aims to restore microbial balance on the skin and reduce inflammation without causing irritation or corrosion. Its primary indication is the management of moderate-to-severe EGFRi-associated rash in cancer patients undergoing targeted therapies[2][3][6].
- Other names
- SE484SE-484SE 484
02
Targets
IL1RL2 (Interleukin 36 Receptor)MSSA (Methicillin-susceptible Staphylococcus aureus)
Beyond the preview
Go deeper on ATR04-484.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATR04-484.